• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SYNTAX score II 可预测单支或双支血管病变患者的长期死亡率。

SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease.

机构信息

Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands.

Department of Cardiology, Amphia Ziekenhuis, Breda, The Netherlands.

出版信息

PLoS One. 2018 Jul 2;13(7):e0200076. doi: 10.1371/journal.pone.0200076. eCollection 2018.

DOI:10.1371/journal.pone.0200076
PMID:29965993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6028142/
Abstract

OBJECTIVE

SYNTAX score II (SSII) is a long-term mortality prediction model to guide the decision making of the heart-team between coronary artery bypass grafting or percutaneous coronary intervention (PCI) in patients with left main or three-vessel coronary artery disease. This study aims to investigate the long-term predictive value of SSII for all-cause mortality in patients with one- or two-vessel disease undergoing PCI.

METHODS

A total of 628 patients (76% men, mean age: 61±10 years) undergoing PCI due to stable angina pectoris (43%) or acute coronary syndrome (57%), included between January 2008 and June 2013, were eligible for the current study. SSII was calculated using the original SYNTAX score website (www.syntaxscore.com). Cox regression analysis was used to assess the association between continuous SSII and long-term all-cause mortality. The area under the receiver-operating characteristic curve was used to assess the performance of SSII.

RESULTS

SSII ranged from 6.6 to 58.2 (median: 20.4, interquartile range: 16.1-26.8). In multivariable analysis, SSII proved to be an independent significant predictor for 4.5-year mortality (hazard ratio per point increase: 1.10; 95% confidence interval: 1.07-1.13; p<0.001). In terms of discrimination, SSII had a concordance index of 0.77.

CONCLUSION

In addition to its established value in patients with left main and three-vessel disease, SSII may also predict long-term mortality in PCI-treated patients with one- or two-vessel disease.

摘要

目的

SYNTAX 评分 II(SSII)是一种长期死亡率预测模型,用于指导左主干或三支血管病变患者的心脏团队在冠状动脉旁路移植术或经皮冠状动脉介入治疗(PCI)之间做出决策。本研究旨在探讨 SSII 对接受 PCI 的单支或双支病变患者全因死亡率的长期预测价值。

方法

共有 628 名(76%为男性,平均年龄:61±10 岁)因稳定性心绞痛(43%)或急性冠状动脉综合征(57%)接受 PCI 的患者符合本研究条件。使用原始 SYNTAX 评分网站(www.syntaxscore.com)计算 SSII。使用 Cox 回归分析评估连续 SSII 与长期全因死亡率之间的关联。使用接收者操作特征曲线下面积评估 SSII 的性能。

结果

SSII 范围为 6.6 至 58.2(中位数:20.4,四分位距:16.1-26.8)。多变量分析表明,SSII 是 4.5 年死亡率的独立显著预测因子(每增加 1 分的危险比:1.10;95%置信区间:1.07-1.13;p<0.001)。在判别能力方面,SSII 的一致性指数为 0.77。

结论

除了在左主干和三支血管病变患者中的既定价值外,SSII 还可能预测接受 PCI 治疗的单支或双支病变患者的长期死亡率。

相似文献

1
SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease.SYNTAX score II 可预测单支或双支血管病变患者的长期死亡率。
PLoS One. 2018 Jul 2;13(7):e0200076. doi: 10.1371/journal.pone.0200076. eCollection 2018.
2
Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial.三支血管冠状动脉疾病的风险分层:在SYNTAX II试验的心脏团队讨论中应用SYNTAX评分II
Catheter Cardiovasc Interv. 2015 Nov 15;86(6):E229-38. doi: 10.1002/ccd.25907. Epub 2015 May 6.
3
Assessment of long-term mortality in patients with complex coronary artery disease undergoing percutaneous intervention: comparison of multiple anatomical and clinical prognostic risk scores.评估接受经皮冠状动脉介入治疗的复杂冠状动脉疾病患者的长期死亡率:多种解剖学和临床预后风险评分的比较。
EuroIntervention. 2017 Nov 20;13(10):1177-1184. doi: 10.4244/EIJ-D-16-00659.
4
Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and/or unprotected left main disease.因多支血管和/或无保护左主干病变接受经皮冠状动脉介入治疗的稳定型心绞痛患者血清尿酸水平与SYNTAX评分II及长期死亡率的相关性
Int J Cardiovasc Imaging. 2019 Jan;35(1):1-7. doi: 10.1007/s10554-018-1446-6. Epub 2018 Aug 24.
5
Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST and PRECOMBAT Randomized Controlled Trials.多支血管病变和/或无保护左主干病变患者行冠状动脉支架置入术或旁路移植术的个体长期死亡率预测:SYNTAX II 评分模型在 BEST 和 PRECOMBAT 随机对照试验 1480 例患者中的外部验证。
JACC Cardiovasc Interv. 2016 Aug 8;9(15):1564-72. doi: 10.1016/j.jcin.2016.04.023.
6
Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy.经皮冠状动脉介入治疗的左主干冠状动脉疾病患者中不遵循SYNTAX评分II手术推荐的影响:EXCEL子研究
Eur J Cardiothorac Surg. 2020 Apr 1;57(4):676-683. doi: 10.1093/ejcts/ezz274.
7
Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease-analysis of CREDO-Kyoto registry.Syntax评分II在左主干和多支冠状动脉疾病患者中的预测性能——CREDO-Kyoto注册研究分析
Circ J. 2014;78(8):1942-9. doi: 10.1253/circj.cj-14-0204. Epub 2014 Jul 7.
8
Assessment of Predictive Value of SYNTAX-II Score for Adverse Cardiac Events and Clinical Outcomes in Patients With Acute Coronary Syndrome.急性冠状动脉综合征患者中SYNTAX-II评分对不良心脏事件和临床结局的预测价值评估
Angiology. 2024 Sep;75(8):754-763. doi: 10.1177/00033197231181958. Epub 2023 Jun 9.
9
Comparison of multiple risk scores in assessing medium-to long-term clinical outcomes in unstable angina / non-ST-elevation myocardial infarction patients undergoing multi vessel percutaneous coronary intervention: An observational, registry-based study in India.比较多种风险评分在评估行经皮冠状动脉介入治疗多支血管不稳定型心绞痛/非 ST 段抬高型心肌梗死患者的中-长期临床结局中的作用:印度一项基于观察性登记研究。
Indian Heart J. 2021 Sep-Oct;73(5):555-560. doi: 10.1016/j.ihj.2021.08.001. Epub 2021 Aug 5.
10
ApPropriateness of myocaRdial RevascularizatiOn assessed by the SYNTAX score II in a coUntry without cardiac Surgery faciliTies; PROUST study.在一个没有心脏外科手术设施的国家,通过SYNTAX评分II评估心肌血运重建的适宜性;PROUST研究。
Int J Cardiol. 2017 Jan 15;227:478-484. doi: 10.1016/j.ijcard.2016.11.001. Epub 2016 Nov 3.

引用本文的文献

1
Comparison of machine learning models with conventional statistical methods for prediction of percutaneous coronary intervention outcomes: a systematic review and meta-analysis.用于预测经皮冠状动脉介入治疗结果的机器学习模型与传统统计方法的比较:一项系统评价和荟萃分析。
BMC Cardiovasc Disord. 2025 Apr 23;25(1):310. doi: 10.1186/s12872-025-04746-0.
2
Utilization of SYNTAX Score II for Predictive Clinical Outcomes in Patients with Coronary Artery Disease and Chronic Renal Insufficiency Following Percutaneous Coronary Intervention.应用SYNTAX评分II预测冠状动脉疾病合并慢性肾功能不全患者经皮冠状动脉介入治疗后的临床结局
Rev Cardiovasc Med. 2024 Oct 22;25(10):371. doi: 10.31083/j.rcm2510371. eCollection 2024 Oct.
3

本文引用的文献

1
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.新型经皮冠状动脉血运重建术治疗初发三血管病变患者的临床结局:SYNTAX II 研究 1 年结果。
Eur Heart J. 2017 Nov 7;38(42):3124-3134. doi: 10.1093/eurheartj/ehx512.
2
Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials.SYNTAX 评分 I 和 II 对合并多支血管病变糖尿病患者的影响:SYNTAX、PRECOMBAT 和 BEST 试验患者水平数据的汇总分析。
Eur Heart J. 2017 Jul 1;38(25):1969-1977. doi: 10.1093/eurheartj/ehx138.
3
Clinical Updates in Coronary Artery Disease: A Comprehensive Review.
冠状动脉疾病的临床进展:全面综述
J Clin Med. 2024 Aug 6;13(16):4600. doi: 10.3390/jcm13164600.
4
Prognostic values of SYNTAX score II in patients with coronary artery disease undergoing percutaneous coronary intervention - Cohort study.SYNTAX 评分 II 对行经皮冠状动脉介入治疗的冠心病患者的预后价值 - 队列研究。
Indian Heart J. 2024 Mar-Apr;76(2):108-112. doi: 10.1016/j.ihj.2024.02.005. Epub 2024 Mar 5.
5
Circulating mir-483-5p as a novel diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after PCI.循环 mir-483-5p 作为急性冠状动脉综合征的新型诊断生物标志物及其对 PCI 后临床结局的预测价值。
BMC Cardiovasc Disord. 2023 Jul 18;23(1):360. doi: 10.1186/s12872-023-03387-5.
6
Relationship between the triglyceride-glucose index and the SYNTAX score 2 in patients with non-ST elevation myocardial infarction.非ST段抬高型心肌梗死患者甘油三酯-葡萄糖指数与SYNTAX评分2的关系
Cardiovasc Endocrinol Metab. 2023 Jan 5;12(1):e0277. doi: 10.1097/XCE.0000000000000277. eCollection 2023 Mar.
7
Prognostic value of syntax score, intravascular ultrasound and near-infrared spectroscopy to identify low-risk patients with coronary artery disease 5-year results from the ATHEROREMO and IBIS-3 cohorts.Syntax 评分、血管内超声和近红外光谱对冠心病低危患者的预后价值:来自 ATHEROREMO 和 IBIS-3 队列的 5 年结果。
PLoS One. 2022 Nov 10;17(11):e0275592. doi: 10.1371/journal.pone.0275592. eCollection 2022.
8
Use of the SYNTAX Score II to predict mortality in interventional cardiology: A systematic review and meta-analysis.使用SYNTAX评分II预测介入心脏病学中的死亡率:一项系统评价和荟萃分析。
Medicine (Baltimore). 2019 Jan;98(2):e14043. doi: 10.1097/MD.0000000000014043.
Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease: An External Validation of the SYNTAX Score II Model in the 1,480 Patients of the BEST and PRECOMBAT Randomized Controlled Trials.
多支血管病变和/或无保护左主干病变患者行冠状动脉支架置入术或旁路移植术的个体长期死亡率预测:SYNTAX II 评分模型在 BEST 和 PRECOMBAT 随机对照试验 1480 例患者中的外部验证。
JACC Cardiovasc Interv. 2016 Aug 8;9(15):1564-72. doi: 10.1016/j.jcin.2016.04.023.
4
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南:欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗工作组编写,欧洲心脏病学会心力衰竭协会(HFA)提供特别贡献。
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
5
Second vs. First generation drug eluting stents in multiple vessel disease and left main stenosis: Two-year follow-up of the observational, prospective, controlled, and multicenter ERACI IV registry.第二代与第一代药物洗脱支架治疗多支血管病变和左主干狭窄:观察性、前瞻性、对照、多中心ERACI IV注册研究的两年随访
Catheter Cardiovasc Interv. 2017 Jan;89(1):37-46. doi: 10.1002/ccd.26468. Epub 2016 Mar 7.
6
Modifying angiographic syntax score according to PCI strategy: lessons learnt from ERACI IV Study.根据经皮冠状动脉介入治疗(PCI)策略修改血管造影术语法评分:从ERACI IV研究中获得的经验教训。
Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):418-20. doi: 10.1016/j.carrev.2015.07.001. Epub 2015 Jul 11.
7
Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease-analysis of CREDO-Kyoto registry.Syntax评分II在左主干和多支冠状动脉疾病患者中的预测性能——CREDO-Kyoto注册研究分析
Circ J. 2014;78(8):1942-9. doi: 10.1253/circj.cj-14-0204. Epub 2014 Jul 7.
8
Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study.基于血管内超声检测的冠状动脉斑块表型与遗传特征和新型循环生物标志物的关系:atheroremovius 研究的原理和设计。
EuroIntervention. 2014 Dec;10(8):953-60. doi: 10.4244/EIJY13M08_01.
9
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II.解剖学和临床特征指导个体患者冠状动脉旁路移植术与经皮冠状动脉介入治疗决策:SYNTAX 评分 II 的制定和验证。
Lancet. 2013 Feb 23;381(9867):639-50. doi: 10.1016/S0140-6736(13)60108-7.
10
Strategies for multivessel revascularization in patients with diabetes.多血管血运重建策略在糖尿病患者中的应用。
N Engl J Med. 2012 Dec 20;367(25):2375-84. doi: 10.1056/NEJMoa1211585. Epub 2012 Nov 4.